{
    "organizations": [],
    "uuid": "9786b25cdbc60c8f4343a8e1441a14bcb27bbc18",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-dynavax-secures-175-million-in-non/brief-dynavax-secures-175-million-in-non-dilutive-debt-financing-idUSASB0C6BV",
    "ord_in_thread": 0,
    "title": "BRIEF-Dynavax Secures $175 Million In Non-Dilutive Debt Financing",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "Feb 20 (Reuters) - Dynavax Technologies Corp:\n* DYNAVAX SECURES $175 MILLION IN NON-DILUTIVE DEBT FINANCING\n* DYNAVAX TECHNOLOGIES - TO RECEIVE $100 MILLION IN A FIRST TRANCHE AND UP TO AN ADDITIONAL $75 MILLION MAY BE BORROWED IN A SECOND TRANCHE AT DYNAVAX‘S OPTION​\n* DYNAVAX TECHNOLOGIES SAYS CASH POSITION WILL SUPPORT LAUNCH OF HEPLISAV-B FIELD SALES TEAM NEXT WEEK AND PHASE 3 CLINICAL TRIAL OF SD-101 Source text for Eikon: Further company coverage:\n ",
    "published": "2018-02-20T19:59:00.000+02:00",
    "crawled": "2018-02-21T21:16:17.043+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "feb",
        "reuters",
        "dynavax",
        "technology",
        "corp",
        "dynavax",
        "secures",
        "million",
        "debt",
        "financing",
        "dynavax",
        "technology",
        "receive",
        "million",
        "first",
        "tranche",
        "additional",
        "million",
        "may",
        "borrowed",
        "second",
        "tranche",
        "dynavax",
        "dynavax",
        "technology",
        "say",
        "cash",
        "position",
        "support",
        "launch",
        "field",
        "sale",
        "team",
        "next",
        "week",
        "phase",
        "clinical",
        "trial",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}